Clear Cell Adenocarcinoma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2021-10-21
Clinical Trial Update: Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA) [Phase 2]
Phase 2 trial investigating lenvatinib plus pembrolizumab for recurrent gynecological clear cell adenocarcinomas (LARA).